Published in Drug Week, September 8th, 2006
The company simultaneously announced that it has gained exclusive control over the global rights to IDEA-033, after reacquiring for consideration the Northern American license from its previous partner in the territory.
IDEA-033 was outlicensed in February 2003 to McNeil Consumer & Specialty Pharmaceuticals for the U.S. and Canada. The recent shift in the partner's focus to pediatric products provided IDEA with an opportunity to reacquire these IDEA-033 rights. IDEA now...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.